Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-Current Assets (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Non-Current Assets for 7 consecutive years, with $19.5 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 39.34% year-over-year to $19.5 million; the TTM value through Mar 2026 reached $91.4 million, down 47.94%, while the annual FY2025 figure was $20.4 million, 41.08% down from the prior year.
  • Non-Current Assets hit $19.5 million in Q1 2026 for Barinthus Biotherapeutics, down from $20.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $61.4 million in Q2 2023 and bottomed at $19.5 million in Q1 2026.
  • Average Non-Current Assets over 5 years is $46.5 million, with a median of $55.3 million recorded in 2022.
  • Year-over-year, Non-Current Assets skyrocketed 1789.55% in 2022 and then plummeted 58.51% in 2025.
  • Barinthus Biotherapeutics' Non-Current Assets stood at $57.2 million in 2022, then grew by 0.76% to $57.6 million in 2023, then tumbled by 39.96% to $34.6 million in 2024, then tumbled by 41.08% to $20.4 million in 2025, then decreased by 4.42% to $19.5 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $19.5 million, $20.4 million, and $22.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.